The drug ‘Molnupiravir’ for the treatment of Covid-19 was introduced in India under the brand name “Molnaflu”.

The Drug ‘Molnupiravir’ For The Treatment Of Covid-19 Was Introduced In India Under The Brand Name “Molnaflu”.

Hyderabad, January 6 (Agency). Aurobindo Pharma Limited has launched the drug ‘Molnupiravir’ to treat COVID-19 under the brand name “Molnaflu” in India. A press release issued by the Hyderabad-based drug maker said that Molnupiravir is intended for the treatment of adult Covid-19 patients admitted to hospital.

Previously, Molnupiravir received ‘Emergency Use Approval’ by the ‘Central Drug Standards Control Organization’ (CDSCO). Last year, Aurobindo Pharma partnered with Merck Sharp Dohme, Singapore, a US-based subsidiary of Merck & Co, for supply and production in low- and middle-income countries.

Also Read: Premiere of Ratnakar Kumar’s ‘Babul’ Movie in Bhojpuri

Aurobindo Vice President and Managing Director K. Nithyananda Reddy said: “We are pleased to have obtained timely approval from the DGCI for the licensed version of Molnupiravir. This will enable affordable treatment for COVID-19 patients and allow us to fight the pandemic through effective, high-quality pharmaceuticals.”

The post-Covid-19 treatment drug ‘Molnupiravir’ introduced in India under the brand name ‘Molnaflu’ first appeared on

Baca Juga :  How to grow Swiss chard

You May Also Like